PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Prime Medicine, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.83+0.36 (+10.37%)

Close on Oct 19, 2026

Market cap: $678.77M
P/E (TTM): –
Dividend yield: –

Prime Medicine, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	4.63	2.98	0	0	0	5.21
Research & Development	161	155	148	87	71	2.98
General & Administrative	52	50	43	30	14	3.16
Operating Expenses	213	205	205	117	84	6.14
Operating Income	-208	-202	-205	-117	-84	-0.93
Interest & Investment Income	4.15	3.52	2.81	–	–	–
Other Non-Operating Income	7.21	6.59	6.38	-6.23	-81	-0.61
Gain (Loss) on Sale of Assets	–	0	-0.03	-0.01	0	0
Income Tax Expense	0	0	-0.28	-0.95	-0.49	1.87
Net Income	-201	-196	-198	-122	-165	-3.41
Preferred Dividends	–	–	0	20	17	0
Net Income to Common	-201	-196	-198	-142	-184	-5.06
EPS (Basic)(per share)	-1.35	-1.65	-2.18	-4.19	-14.19	-1.91
EPS (Diluted)(per share)	-1.35	-1.65	-2.18	-4.19	-14.19	-1.91
Shares Outstanding (Basic, Weighted)(shares)	149	119	91	34	13	2.64
Shares Outstanding (Diluted, Weighted)(shares)	149	119	91	34	13	2.64
EBITDA	-201	-196	-200	-114	-84	-0.89

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -4242.7%
Net margin: -4056.4%
Return on equity, FY2025: -146.8%

Financial strength

Current ratio: 3.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 149.7%

Valuation

P/E ratio: –
Price to sales: 146.54
Price to book: 17.05
Dividend yield: –